Edwards Lifesciences Corporation $EW Shares Bought by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 28.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,952 shares of the medical research company’s stock after acquiring an additional 884 shares during the period. Pallas Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $309,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in EW. Nuveen LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $330,881,000. Jennison Associates LLC grew its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $92,631,000. Woodline Partners LP grew its holdings in Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after purchasing an additional 814,917 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after purchasing an additional 709,648 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a report on Friday, July 25th. Truist Financial raised their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Barclays raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $87.17.

Edwards Lifesciences Stock Down 0.2%

Edwards Lifesciences stock opened at $74.39 on Monday. The stock has a market cap of $43.67 billion, a price-to-earnings ratio of 10.70, a PEG ratio of 3.59 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $78.69 and its two-hundred day moving average price is $75.56. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.